Tianyin Pharmaceutical Co., Inc. Appoints Mr. Tao Yang as Chief Operating Officer

Tianyin Pharmaceutical Co., Inc. Appoints Mr. Tao Yang as Chief Operating Officer

CHENGDU, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced the appointment of Mr. Tao Yang to the position of Chief Operating Officer. Mr. Yang was appointed in November 2008 as Chief Advisor for Sales and Marketing and Special Advisor to Dr. Jiang, the CEO of Tianyin Pharmaceutical Co., Inc.

Mr. Yang, age 42, is a well-known certified pharmaceutical sales training specialist with more than 18 years experience in the sales and marketing industry. His experience includes serving as a sales training specialist and marketing manager for Astra Zeneca and Bayer, in addition to managing the training services for 85 well-known domestic and international pharmaceutical companies during the past ten years. These include Grunenthal-San Huan Pharmaceutical (China) Co., Ltd., Beaufour Ipsen Pharmaceutical Co., Ltd., and Yangtze River Pharmacy Group, etc. Mr. Yang also served as BPIP implementation consultant for CPDF, launched by the World Bank in 2001, and the executive advisor of a policy system program in 2007, which is a training system formed by the Chinese and British government aiming to support domestic small to medium sized businesses.

Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, said, "We are very pleased to have Mr. Yang join our senior management team as Chief Operating Officer as his industry experience and dedication will be proved invaluable for Tianyin. During the past year Mr. Yang has helped implement a strategy to boost sales of our leading products while further improving the functionality of our sales and marketing team. The success of Mr. Yang's efforts can be evidenced by our fourth quarter financial results and we believe the plan he has helped establish for Tianyin will contribute to accelerating year-over-year growth during fiscal 2010."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 40 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $43 million and net income of approximately $7.9 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO China
     Tel:   +86-158-2122-5642
     Email: [email protected]

    Investors:
     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: [email protected]

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.